About Kizzmekia Corbett-Helaire

COVID-19 Vaccine Development and mRNA Innovation

Kizzmekia Corbett-Helaire played a pivotal role in the rapid development of the COVID-19 mRNA vaccine, recounting the intense '66 days' from concept to emergency authorization.[3] She contributed significantly to Moderna’s vaccine, earning the 2024 Hans Sigrist Prize for her mRNA advancements.[2][7] Corbett-Helaire discussed boosters and ongoing vaccine strategies in interviews, highlighting adaptability to variants.[4]

Current Research Focus: Glycans and Coronaviruses

Her Corbett Lab investigates glycans' roles in endemic coronaviruses, viral infection mechanisms, and immune responses.[6] The lab's work extends beyond COVID-19 to broader coronavirus immunology, supported by her endowed professorship.[9]

Awards, Honors, and Recognitions

Corbett-Helaire has received numerous accolades, including the 2024 Hans Sigrist Prize,[2][7] 2025 Pew Biomedical Scholar,[10][13] Building the Foundation Award,[5][11] and selection as a 2026 TED Fellow.[8][12] These recognize her foundational contributions to vaccines and biomedical science.

Public Engagement and Science Communication

She engages in high-profile discussions, such as with Francis Collins on faith and science,[1] and speaks on vaccines for the future.[7] Her media presence amplifies immunology insights and public health education.[2]

Diversity, Inclusion, and Social Impact

As a Black woman in science, her work embodies diversity and inclusion efforts, aligned with topics like social impact and education. Awards like Building the Foundation highlight her role in equitable science foundations.[5]